SCHEMBL1912413

SCHEMBL1912413

Cc1cc(-c2ncc(CN)cc2C)ccn1

nearest known ligand 0.52

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 18/20 0.52
PORCN Q9H237 1/20 0.47
NSD3 Q9BZ95 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL249352 0.98 WNT3A (0.51) WNT3APORCNNSD3
SCHEMBL1912424 0.86 LOXL2 (0.53) WNT3ANSD3
SCHEMBL14802467 0.86 WNT3A (0.53) WNT3A
SCHEMBL22148134 0.86 WNT3A (0.53) WNT3APORCN
SCHEMBL24767108 0.82 LOX (0.56) WNT3ANSD3
SCHEMBL18703835 0.82 DYRK1A (0.44) WNT3A
SCHEMBL1912302 0.81 LOXL2 (0.55) WNT3ANSD3
SCHEMBL18703808 0.81 WNT3A (0.47) WNT3A
SCHEMBL22147865 0.81 WNT3A (0.58) WNT3APORCN
SCHEMBL10259457 0.81 WNT3A (0.58) WNT3APORCN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3388428-B1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) 2021-08-04 EP disclosed
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2020-11-03 US disclosed
WO-2017097216-A9 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR 杭州雷索药业有限公司 2017-11-23 WO disclosed
WO-2017097216-A1 FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR 杭州雷索药业有限公司 2017-06-15 WO disclosed
US-9181235-B2 Substituted pyridines for modulating the WNT signaling pathway NOVARTIS AG (CH) 2015-11-10 US disclosed
US-9181235-B2 Substituted pyridines for modulating the WNT signaling pathway NOVARTIS AG (CH) 2015-11-10 US disclosed
EP-2588453-B1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY NOVARTIS AG (CH) 2015-04-01 EP disclosed
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY NOVARTIS AG (CH) 2013-03-28 US disclosed
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY NOVARTIS AG (CH) 2013-03-28 US disclosed
WO-2012003189-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY IRM LLC (BM) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10821104-B2 Five-membered heterocyclic amides WNT pathway inhibitor WNT1, WNT3, WNT3A WNT3A 3/4885PORCN 516/4885NSD3 508/4885
US-20130079328-A1 COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY WNT3A, WNT1, WNT3 WNT3A 1/4885PORCN 2259/4885NSD3 989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.